Study of Ruxolitinib Treatment in Adults With Primary or Secondary Myelofibrosis Observing Long-Term Survival and Disease Characteristics

What this Trial Is About

This research aims to understand how clinical and laboratory features of myelofibrosis affect patients long-term survival when treated with ruxolitinib. It focuses on adults diagnosed with primary myelofibrosis or secondary myelofibrosis related to essential thrombocythemia or polycythemia vera. The study is observational, involving multiple centers, and includes both retrospective and prospective patient groups. Participants are those who have started ruxolitinib treatment as part of their usual care, without influence from the study itself. The study collects data from laboratory tests, histological, cytogenetic, molecular, and radiologic exams done during routine care. Information on symptoms and spleen enlargement is gathered at diagnosis and during regular disease assessments. Each patient is observed for a minimum of three months, with the overall study lasting up to ten years. During the study, researchers collect and review medical records, test results, and imaging done in normal clinical practice to analyze outcomes such as long-term survival. They also evaluate factors like peripheral blood blasts, specific genetic mutations, and adverse events related to treatment. The study aims to validate prognostic tools and monitor safety over a long period, ensuring participants receive their standard medical care throughout.

Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera